Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements
Related Experiment Video
Updated: Jul 24, 2025
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Christopher G Cann1, Michael B LaPelusa1, Sarah K Cimino2
1Department of Medicine: Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, United States.
Abstract:
Colorectal cancer results in the deaths of hundreds of thousands of patients worldwide each year, with incidence expected to rise over the next two decades. In the metastatic setting, cytotoxic therapy options remain limited, which is reflected in the meager improvement of patient survival rates. Therefore, focus has turned to the identification of the mutational composition inherent to colorectal cancers and development of therapeutic targeted agents. Herein, we review the most up to date systemic treatment strategies for metastatic colorectal cancer based on the actionable molecular alterations and genetic profiles of colorectal malignancies.
Insights
Metastatic colorectal cancer survival rates are poor due to limited treatment options. This review explores targeted therapies based on molecular alterations for improved outcomes in colorectal cancer patients.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Colorectal cancer causes significant global mortality, with increasing incidence projected.
- Current cytotoxic therapies offer limited survival benefits for metastatic colorectal cancer.
- There is a critical need for novel therapeutic strategies in advanced colorectal cancer.
Purpose of the Study:
- To review current systemic treatment strategies for metastatic colorectal cancer.
- To focus on therapies targeting actionable molecular alterations.
- To provide an overview of genetic profiles influencing treatment decisions.
Main Methods:
- Literature review of recent advancements in metastatic colorectal cancer treatment.
- Analysis of studies focusing on molecularly targeted agents.
- Synthesis of data on genetic profiling and its therapeutic implications.
Main Results:
- Identification of key molecular targets in colorectal cancer.
- Evaluation of the efficacy of targeted therapies in clinical trials.
- Discussion of personalized medicine approaches based on genetic profiles.
Conclusions:
- Targeted therapies based on molecular alterations represent a promising frontier for metastatic colorectal cancer.
- Understanding the genetic landscape of colorectal tumors is crucial for effective treatment selection.
- Personalized treatment strategies are essential to improve survival rates in advanced colorectal cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...